

Weight of Evidence Inference and Bayesian Nomograms Using Genomic Feature Pairs


Sebastian Gomez

Mentor: Dr. Pablo Tamayo



Why do we care?

- •Despite significant progress in recent years clinical prediction and stratification of risk in patients remains a challenge
- •The focus has shifted from clinical parameters to molecular markers. e.g. expression of specific genes and selected genomic abnormalities




Purpose of the research

•Develop a way of predicting a particular outcome based on several input features (risk factors)

Examples:

•Clinical Prognosis: Predicting the probability of responding to treatment in different cancer types



+ OUR MODEL =




Our predictions are based on evidence provided by features

- Over-expression of gene or pathway
- Genomic abnormality: amplification
- Genomic abnormality: deletion

Types of outcomes we want to predict


- Response to treatment (e.g. chemo)
- Platinum Status (platinum sensitive or resistant)

Pathway rather than gene features are used in model



Survival of platinum resistant patients versus sensitive patients in ovarian cancer

70 Resistant patients vs 156 Sensitive patients Likelihood ratio 51.61, p-value 0




Platinum Resistant: recurrence of cancer within the first 6 months after platinum therapy.

Platinum Sensitive: No recurrence of cancer within the first 6 months after treatment


Nomograms are a graphical way of representing a classification model



Ovarian cancer Bayesian nomogram for a specific patient. Showing 5 out of 12 total single features (current model used)




Current model for ovarian cancer has two main issues: features are strongly correlated and there are a lot of errors made even when sufficient evidence is available.




One way of improving these results is using pairs of features instead of single features

- •Important things to know about dealing with pairs of features:
 - •The evidence of a pair is not the same as the sum of the individual evidences.
 - •Before, we had n features, now we have $(n^2 n)/2$ possible pairs of features
 - •Pairs not only perform better, they also have the potential to uncover interesting

How did I approach this problem?



Ovarian cancer pairs work well because they correct each other's mistakes and they reinforce each other when correct.





Feature 1: genes down regulated by AKT (oncogene)

Feature 2: genes up regulated by KRAS (oncogene)


Intensity of color represents the certainty of the prediction. Red represents sensitive prediction and blue represents resistant prediction

Here's how we visualize pairs of features in a nomogram





Ovarian cancer pairs show a lesser degree of correlation than single features



Comparison of models for ovarian cancer. Both ROC and Error rate improvement from using pairs

Model	au-ROC	Error Rate	# of features
Singles	0.595	42.3%	12
Pairs	0.681	30.7%	6 pairs



Real Outcome

Platinum Status	Correct	Incorrect
Resistant	20	15
Sensitive	73	29



Comparison of models for Medulloblastoma

Model	au-ROC	Error Rate	# of features
Α	0.727	32.1%	2
В	0.747	34.6%	3
С	0.802	25.6%	46
D	0.782	25.6%	53
Pairs	0.803	29.5%	5 pairs + 2 singles



Conclusion

- Pairs are better at predicting outcome
- The fact that pairs "work together" might uncover interesting interactions between the features
- Pairs dramatically reduce the correlation in the model
- Naïve Bayesian is a simple approach that physicians can understand and is as accurate as more complex models



Datasets:

- Medulloblastoma Dataset
 - •Training Set: 94 samples multi-institutional
 - Children's Hospital (Boston)
 - Children Oncology Group (COG)
 - •U of Washington Medical Center
 - Children's Hospital (Texas)
 - •The Johns Hopkins Medical Center
 - •Independent test set: 78 samples multi-institutional
 - •47 samples, Pomeroy et al. 2002
 - •16 samples, Kool et al. 2008
 - •15 samples, COG 2009



Data Acknowledgement

Datasets:

- Ovarian Cancer Datasets
 - Toothill
 - •TCGA



Acknowledgements

I would like to thank the following people for their contributions:
Roel Verhaak
Jill Mesirov
Todd Golub
Scott Pomeroy

I would also like to thank the following people for all their support. Eboney Smith Jacqueline Nkuebe Bruce Birren



•Conditional Probabilities & Bayes Theorem for independent features:

$$P(r \mid x_1, x_2, ..., x_n) = \frac{P(r, x_1, x_2, ..., x_n)}{P(x_1, x_2, ..., x_n)} = P(r \mid x_1)P(r \mid x_2)...P(r \mid x_n)$$

•Weight of Evidence for target r and state x:

•Total evidence that feature x provides:

AvEv(r | x) =
$$\sum_{i=1}^{|X|} P(x = X_i) |Ev(r | x = X_i)|$$
 Where X = {Male, Female}



Computing evidence for pairs

•Very similar to computing the evidence for singles

Ev(r=yes | x=female, y = adult) =
$$log = \frac{P(r = yes | x = female, y = adult) / P(r = no | x = female, y = adult)}{P(r = yes) / P(r = no)}$$

•Remember Bayes Theorem:

$$P(r=yes \mid x=female, y=adult) = P(x=female, y=adult) = P(x=female, y=adult)$$

•Total evidence that pair of features x, y provides:

AvEv(r | x, y) =
$$\sum_{i=1}^{|X|} \sum_{j=1}^{|Y|} P(x = X_i, y = Y_j) |Ev(r | x = X_i, y = Y_j)|$$

Where X = {Male, Female} Where Y = {Adult, Child}

